Latest Kidney Cancer News

Odds of Prescribing Drugs Up With Doc Receipt of Payments
Doctors who receive general payment for cancer drug more likely to prescribe drug marketed by company.

Relative Visceral Fat Indicates Mortality Risk for Women With RCC
An evaluation of patients with clear cell renal cell carcinoma revealed greater risk of death for female patients with high relative visceral fat area (rVFA), highlighting the significance of metabolic differences between men and women.

Myocarditis Rare Side Effect of Immune Checkpoint Inhibitors
Myocarditis with ICIs may be more common than initially thought; responds to higher steroid dosages

Older Age May Up Risk for RCC-Related Death After Surgery
The risk of dying from pT1a renal cell carcinoma after partial or radical nephrectomy increases along with patient age.

Nivolumab Plus Ipilimumab Better for Advanced RCC
Among intermediate- and poor-risk patients, the risk for death was 37% lower with nivolumab plus ipilimumab than with sunitinib.

Robotic PN May Offer Better Outcomes Than RFA for T1a RCC
Two-year recurrence-free survival was 100% vs 95.2% among robotic surgery and radiofrequency ablation patients, respectively.

Small Renal Masses Initially Grow at Variable Rates
Not reliable predictor of adverse outcomes in those under active surveillance; less variability over time

First-line Pazopanib May Improve Outcomes in Advanced RCC
Treatment-naïve patients with advanced clear-cell renal cell carcinoma had significantly longer progression-free survival when treated with pazopanib instead of temsirolimus.

Metastatic RCC Treatment With Nivolumab Confirmed Safe, Efficacious
The safety and efficacy of nivolumab for treating metastatic renal cell carcinoma is comparable to that found in the CheckMate 025 trial.

Axitinib-Pembrolizumab Combo Promising for Advanced RCC
In a phase Ib study, dual therapy with axitinib and pembrolizumab was well tolerated and demonstrated antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.

Cytoreductive Nephrectomy May Up Survival in Papillary mRCC
Study reveals a 38% decreased risk of death in patients with papillary metastatic renal cell carcinoma who undergo cytoreductive nephrectomy vs those who do not.

Metastatic Kidney Cancer Outcomes Improved With Combined Therapy
Immunotherapy with atezolizumab plus targeted therapy with bevacizumab improves progression-free survival better than sunitinib in patients with untreated metastatic renal cell carcinoma.

Urologic Cancer Surgery Readmission Rate Highest for RC
In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.

Robotic Partial Nephrectomy Feasible for Larger Kidney Tumors
No greater risks for upstaging or positive surgical margins were observed among patients who underwent RPN for cT2a tumors over the short term.

Kidney Cancer Progression Linked to Preop Cardiovascular Biomarkers
Elevated serum levels of BNP and NT-proBNP prior to nephrectomy are associated with an increased likelihood of RCC progression.
Renal and Urology News Articles
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Anemia
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetes
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Hemodialysis
- Hyperphosphatemia
- Hypertension
- Hyperuricemia
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)
- Transplantation